RxDoctor Payments Data

Allen Greenbaum, MD

Ophthalmology · Harrison, NYNPI 1891739728

Payments from drug & device makers

$9,570in general payments, 2019–2025

Across 353 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$972
  • Rxsight Inc$655
  • Aerie Pharmaceuticals, Inc.$577
  • Kala Pharmaceuticals, Inc.$473
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$9,570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,570 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$572,654
Medicare patients
1,760
Services billed
4,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine70$89,973
LumiganBimatoprost158$77,928
RocklatanNetarsudil Mesylat/Latanoprost30$20,945
CequaCyclosporine23$20,730
VyzultaLatanoprostene Bunod15$12,796
CombiganBrimonidine Tartrate/Timolol30$12,493
MieboPerfluorohexyloctane/Pf12$9,887
SimbrinzaBrinzolamide/Brimonidine Tart25$6,975
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat153$3,615
Latanoprost260$3,305
Tobramycin-DexamethasoneTobramycin/Dexamethasone54$3,237
Prednisolone Acetate78$3,025
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$2,485
Fluorometholone26$2,433
Bromfenac Sodium13$1,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,505$180,395258 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$444$22,68327 claims
Aerie Pharmaceuticals, Inc.Rocklatan$577$20,94530 claims
Sun Pharmaceutical Industries Inc.Cequa$972$20,73023 claims
AlconSimbrinza$2,060$6,97525 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$91$1,63511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Harrison

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →